Is pomalidomide a chemotherapy drug or a targeted drug? What is its drug class and mechanism?

Pomalidomide (Pomalidomide) is not a chemotherapy drug in the traditional sense, but a targeted drug that belongs to the class of immunomodulatory drugs (IMiD). Its mechanism of action is different from traditional chemotherapy drugs. It mainly exerts its therapeutic effect by regulating the immune system and inhibiting the growth of tumor cells. Pomalidomide has a significant effect in the treatment of multiple myeloma and other cancers, and is often used as a second-line treatment drug, especially when patients are resistant to other treatments (such as raltitrexed, mafatinib, etc.).

The main pharmacological mechanism of pomalidomide involves its modulatory effect on the immune system. It enhances the response of immune cells in the body, especially T cells and natural killer cells (NK cells), allowing these immune cells to more effectively recognize and kill tumor cells. In addition, pomalidomide also inhibits angiogenesis in the tumor microenvironment, reducing the blood supply to tumor cells and further inhibiting tumor growth. Therefore, pomalidomide is classified as an immunomodulatory drug rather than a traditional chemotherapy drug.

Unlike chemotherapy drugs, pomalidomide works through immune-mediated mechanisms rather than directly killing cells through toxic effects. Chemotherapy drugs usually kill cancer cells by inhibiting the proliferation of cancer cells or directly damaging DNA, but pomalidomide mainly relies on activating the immune system in the body and stimulating immune cells to exert anti-tumor effects. Due to its different mechanism, pomalidomide generally has milder side effects than chemotherapy drugs, especially when used long-term.

In general, pomalidomide is a targeted drug that belongs to the category of immunomodulatory drugs (IMiD), which exerts anti-tumor effects by regulating the immune system and inhibiting angiogenesis. Unlike traditional chemotherapy drugs, it does not rely on directly killing cancer cells, but controls tumor growth by enhancing immune responses, so it has unique efficacy and advantages in the treatment of multiple myeloma and other diseases.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide